The success of GLP-1s has prompted biotechs to approach the challenge differently. After years of false starts and disappointing results, longevity drugs could be on the horizon. Do immigrants from some countries commit more sex crimes? And the big business of miniatures.
Guests and host:
Topics covered:
Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
","author_name":"The Economist"}